

Product datasheet for TL316771V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Rad6 (UBE2A) Human shRNA Lentiviral Particle (Locus ID 7319)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Rad6 (UBE2A) Human shRNA Lentiviral Particle (Locus ID 7319)

Locus ID: 7319

Synonyms: HHR6A; MRXS30; MRXSN; RAD6A; UBC2

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: UBE2A - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001282161, NM 003336, NM 181762, NM 181777, NM 003336.1, NM 003336.2,

NM 003336.3, NM 181762.1, NM 181762.2, NM 181777.1, NM 001282161.1, BC010175,

BC010175.2, BC042021, NM 001282161.2, NM 003336.4, NM 181762.3

UniProt ID: P49459

Summary: The modification of proteins with ubiquitin is an important cellular mechanism for targeting

abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, ubiquitin-conjugating enzymes, and ubiquitin-protein ligases. This gene encodes a member of the E2 ubiquitin-conjugating

enzyme family. This enzyme is required for post-replicative DNA damage repair, and may play

a role in transcriptional regulation. Mutations in this gene are associated with cognitive disability. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug

2013]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Rad6 (UBE2A) Human shRNA Lentiviral Particle (Locus ID 7319) - TL316771V

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).